Exocrine Pancreas Carcinoma — Trials

Exocrine Pancreas Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

918 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 358
Recruiting: 210
Ph III recruiting: 23
Growth YoY: +41.4%
Industry share: 41%
Top sponsor: National Cancer Institute (NCI)
Termination share: 38%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (136)

clinicaltrialsPublishedShowing 251–269 of 269 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00462553	Sunitinib and Gemcitabine in Treating Patients With Pancreatic Cancer or Other Solid Tumors	completed	Phase 1	37	National Cancer Institute (NCI)NIH	1	Feb 24, 2014	clinicaltrials
NCT01145456	Gamma-Secretase Inhibitor RO4929097 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors	completed	Phase 1	18	National Cancer Institute (NCI)NIH	1	Feb 24, 2014	clinicaltrials